Literature DB >> 1874599

Comparative toxicity of fostriecin, hepsulfam and pyrazine diazohydroxide to human and murine hematopoietic progenitor cells in vitro.

D L Du1, D A Volpe, C K Grieshaber, M J Murphy.   

Abstract

The in vitro myelotoxic potentials of three investigational antitumor agents, Fostriecin, Hepsulfam and pyrazine diazohydroxide (PZDH), were evaluated utilizing clonogenic assays. Human and murine marrow cells were exposed to each drug for 1 hr prior to culture in microcapillary (human) or Petri dish (murine) assays. Fostriecin (0.22-220 microM), Hepsulfam (0.34-340 microM) and PZDH (0.68-680 microM) inhibited myeloid (CFU-gm), erythroid (BFU-e, CFU-e) and megakaryocytic (CFU-meg) colony formation in a concentration-dependent manner. CFU-e from both species were more sensitive to Fostriecin than the other progenitors and murine cells more sensitive overall to Fostriecin than their human counterparts. Murine CFU-e were also more sensitive to Hepsulfam than human CFU-e, with CFU-gm and BFU-e being similarly affected in both species. Human BFU-e were greatly inhibited by PZDH, whereas murine BFU-e were relatively resistant to its toxic effects. Fostriecin was the most toxic of the three antitumor agents, with PZDH the least toxic.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1874599     DOI: 10.1007/bf00175082

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  20 in total

1.  Improved plasma culture system for production of erythrocytic colonies in vitro: quantitative assay method for CFU-E.

Authors:  D L McLeod; M M Shreeve; A A Axelrad
Journal:  Blood       Date:  1974-10       Impact factor: 22.113

2.  In vitro erythropoiesis. II. Cytochemical enumeration of erythroid stem cells (CFU-e and BFU-e) from normal mouse and human hematopoietic tissues.

Authors:  V S Gallicchio; M J Murphy
Journal:  Exp Hematol       Date:  1979-05       Impact factor: 3.084

3.  Inhibition of type II topoisomerase by fostriecin.

Authors:  T J Boritzki; T S Wolfard; J A Besserer; R C Jackson; D W Fry
Journal:  Biochem Pharmacol       Date:  1988-11-01       Impact factor: 5.858

4.  Effects of L-phenylalanine mustard and L-buthionine sulfoximine on murine and human hematopoietic progenitor cells in vitro.

Authors:  D L Du; D A Volpe; C K Grieshaber; M J Murphy
Journal:  Cancer Res       Date:  1990-07-01       Impact factor: 12.701

5.  Anticancer activity of the structurally novel antibiotic Cl-920 and its analogues.

Authors:  W R Leopold; J L Shillis; A E Mertus; J M Nelson; B J Roberts; R C Jackson
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

6.  Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system.

Authors:  D W Fry; J A Besserer; T J Boritzki
Journal:  Cancer Res       Date:  1984-08       Impact factor: 12.701

7.  In vitro activity of the novel antitumor antibiotic fostriecin (CI-920) in a human tumor cloning assay.

Authors:  W Scheithauer; D D Von Hoff; G M Clark; J L Shillis; E F Elslager
Journal:  Eur J Cancer Clin Oncol       Date:  1986-08

8.  Chemical structure of carbamoylating groups and their relationship to bone marrow toxicity and antiglioma activity of bifunctionally alkylating and carbamoylating nitrosoureas.

Authors:  F Ali-Osman; J Giblin; M Berger; M J Murphy; M L Rosenblum
Journal:  Cancer Res       Date:  1985-09       Impact factor: 12.701

9.  Pure and mixed erythroid colony formation in vitro stimulated by spleen conditioned medium with no detectable erythropoietin.

Authors:  G R Johnson; D Metcalf
Journal:  Proc Natl Acad Sci U S A       Date:  1977-09       Impact factor: 11.205

10.  Acquisition and clonal growth of human sternal bone marrow obtained incidental to open-heart surgery.

Authors:  K L Wittberg; R A De Wall; M J Murphy
Journal:  Exp Cell Biol       Date:  1985
View more
  6 in total

1.  Automated imaging and quantitation of tumor cells and CFU-GM colonies in microcapillary cultures: toward therapeutic index-based drug screening.

Authors:  M J Murphy; F Fushimi; R E Parchment; E Barberá-Guillem
Journal:  Invest New Drugs       Date:  1996       Impact factor: 3.850

2.  Pyrazine diazohydroxide (NSC-361456). Phase I clinical and pharmacokinetic studies.

Authors:  M V Dhodapkar; R L Richardson; J M Reid; M M Ames
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

3.  Comparative in vitro myelotoxicity of FCE 24517, a distamycin derivative, to human, canine and murine hematopoietic progenitor cells.

Authors:  D A Volpe; D L Du; M G Zurlo; N Mongelli; M J Murphy
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

4.  Hepsulfam distribution in blood, plasma and cerebrospinal fluid of baboons.

Authors:  M V Marshall; K D Carey; D D Von Hoff; J G Kuhn
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

Review 5.  Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity.

Authors:  R E Parchment
Journal:  Environ Health Perspect       Date:  1998-04       Impact factor: 9.031

6.  Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells.

Authors:  M Ghielmini; G Bosshard; L Capolongo; M C Geroni; E Pesenti; V Torri; M D'Incalci; F Cavalli; C Sessa
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.